.jpg?format=webp&width=780)
Nirmatrelvir–ritonavir has been authorized for emergency use by many countries to treat coronavirus disease 2019 (Covid-19). However, the supply falls short of the global demand, which creates a need for more options. VV116 is an oral antiviral agent with potent activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Among adults with mild-to-moderate COVID-19 at risk for progression, VV116 was non-inferior to nirmatrelvir/ritonavir concerning the time to sustained clinical recovery, with fewer safety concerns.
Like
Save
Share